Ubs Asset Management Americas Inc Neurocrine Biosciences Inc Call Options Transaction History
Ubs Asset Management Americas Inc
- $345 Billion
- Q2 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding NBIX
# of Institutions
641Shares Held
95.3MCall Options Held
661KPut Options Held
227K-
Black Rock Inc. New York, NY14.2MShares$1.62 Billion0.04% of portfolio
-
Vanguard Group Inc Valley Forge, PA10.1MShares$1.15 Billion0.03% of portfolio
-
State Street Corp Boston, MA4.61MShares$525 Million0.03% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny2.47MShares$281 Million0.6% of portfolio
-
Jpmorgan Chase & CO New York, NY2.36MShares$269 Million0.03% of portfolio
About NEUROCRINE BIOSCIENCES INC
- Ticker NBIX
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 95,639,296
- Market Cap $10.9B
- Description
- Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...